Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4, which is in Phase III for combination treatment in oncology; POL6014, an inhaled inhibitor of neutrophil elastase, which is in Phase Ib clinical trial for the treatment of cystic fibrosis and other neutrophilic lung diseases; and outer membrane protein targeting antibiotics (OMPTA) platform. The company is also developing POL7306, targeting the most resistant MDR strains of all Gram-negative ESKAPE, including enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, and enterobacter species pathogens; and inhaled murepavadin (POL7080), a precision outer membrane protein targeting antibiotic for the treatment of pseudomonas aeruginosa. Polyphor AG was founded in 1996 and is headquartered in Allschwil, Switzerland.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, 'cheap'
Buy
Sell